Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy: in-vitro optimization and ex-vivo assessment

PURPOSE: Eplerenone (EPL) is a selective mineralocorticoid receptor antagonist used for treatment of chronic central serous chorioretinopathy which characterized by accumulation of subretinal fluid causing a localized area of retinal detachment. unfortunately, EPL suffers from poor oral bioavailabil...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelhakeem, Eman, El-Nabarawi, Mohamed, Shamma, Rehab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023249/
https://www.ncbi.nlm.nih.gov/pubmed/33787445
http://dx.doi.org/10.1080/10717544.2021.1902023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023249/
https://www.ncbi.nlm.nih.gov/pubmed/33787445
http://dx.doi.org/10.1080/10717544.2021.1902023

Ejemplares similares